Tazminat ve Piyasa: Giovanni 'nin toplam tazminatı ($USD 4.52M ), Swiss pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.24M ).

Tazminat ve Kazançlar: Giovanni şirketinin tazminatını şirket performansıyla karşılaştırmak için yeterli veri yok.

CEO

Giovanni Di Napoli (50 yo)

1yr

Görev süresi

€3,995,280

Tazminat

Mr. Giovanni Di Napoli is Chief Executive Officer and Director of Cosmo Pharmaceuticals N.V. from May 24, 2024. He was President of Gastrointestinal at Medtronic plc. He is an accomplished leader with an e...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Alessandro Della Cha	Non Executive Chairman	19.3yrs	€1.77m	Veri yok
Giovanni Di Napoli	CEO & Director	1yr	€4.00m	Veri yok
Mauro Ajani	Founder & Non-Executive Director	19.3yrs	€2.64m	Veri yok
Niall Donnelly	Executive VP of Corporate Governance	less than a year	€690.01k	Veri yok
Svetlana Sigalova	Chief Financial Officer	less than a year	Veri yok	Veri yok
Marco Lecchi	Chief Operating Officer	4.3yrs	Veri yok	Veri yok
Davide Malavasi	Qualified Person & Technical Director	13.7yrs	Veri yok	Veri yok
Luigi Longo	Chief Scientific Officer	3.1yrs	Veri yok	Veri yok
Federico Sommariva	Chief Legal Counsel	less than a year	Veri yok	Veri yok
Roberto Villa	Chief Manufacturing Officer	28.3yrs	Veri yok	Veri yok
Ngo Nhan	President of Cosmo Intelligent Medical Devices	no data	Veri yok	Veri yok
Andrea Cherubini	Chief AI Officer	5.3yrs	Veri yok	Veri yok

3.1yrs

Ortalama Görev Süresi

51yo

Ortalama Yaş

Deneyimli Yönetim: COPN 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Alessandro Della Cha	Non Executive Chairman	19.3yrs	€1.77m	Veri yok
Giovanni Di Napoli	CEO & Director	1yr	€4.00m	Veri yok
Mauro Ajani	Founder & Non-Executive Director	19.3yrs	€2.64m	Veri yok
Niall Donnelly	Executive VP of Corporate Governance	1yr	€690.01k	Veri yok
William Sandborn	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Geert D'Haens	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Silvio Danese	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Maria Roncarolo	Non-Executive Director	13.1yrs	€131.45k	Veri yok
Ralf Kiesslich	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Robert Steffen	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Silvana Perretta	Non-Executive Director	1yr	€131.58k	Veri yok
John O'Dea	Non-Executive Director	1yr	€131.58k	Veri yok

1.0yrs

Ortalama Görev Süresi

60.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: COPN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilmiyor ( 1 yıllık ortalama görev süresi), bu da yeni bir yönetim kurulu olduğunu gösteriyor.

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2025/05/05 06:41
Gün Sonu Hisse Fiyatı	2025/05/05 00:00
Kazançlar	2024/12/31
Yıllık Kazançlar	2024/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Cosmo Pharmaceuticals N.V. 13 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Laura Pfeifer-Rossi	Bank am Bellevue
Silvia Schanz	Bank Vontobel AG
Laura Hindley	Berenberg

Cosmo Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025

Cosmo Pharmaceuticals N.V. Appoints Federico Sommariva as Chief Legal Counsel

Cosmo Pharmaceuticals N.V. Announces the Appointment of Andrea Cherubini as Chief AI Officer

Cosmo Pharmaceuticals N.V. Announces Chief Financial Officer Changes

Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024

Cosmo Pharmaceuticals N.V., Annual General Meeting, May 24, 2024

Recent updates

Cosmo Pharmaceuticals N.V., Annual General Meeting, May 30, 2025

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Investor sentiment deteriorates as stock falls 15%

Cosmo Pharmaceuticals N.V. Appoints Federico Sommariva as Chief Legal Counsel

Full year 2024 earnings: Revenues and EPS in line with analyst expectations

Clascoterone Trials Completion And AI Expansion Will Open Future Markets

Investor sentiment deteriorates as stock falls 17%

Cosmo Pharmaceuticals N.V. Announces the Appointment of Andrea Cherubini as Chief AI Officer

Weekly Picks: NLBR’s vision, MNSO’s expansion plans and COPN’s opportunity

Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Results on Mar 06, 2025

Cosmo Pharmaceuticals Announces Strong Full Year 2024 Revenue and Cash and Provides Business and Pipeline Updates

Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2024 Final Results on Mar 20, 2025

Cosmo Pharmaceuticals N.V.'s (VTX:COPN) P/S Still Appears To Be Reasonable

Cosmo Pharmaceuticals N.V. Announces Chief Financial Officer Changes

First half 2024 earnings released: EPS: €4.72 (vs €0.092 in 1H 2023)

New major risk - Revenue and earnings growth

Upcoming dividend of €2.00 per share

Market Participants Recognise Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Revenues

Cosmo Pharmaceuticals N.V. Announces Executive Changes at the Upcoming Annual General Meeting on 24 May 2024

Cosmo Pharmaceuticals' (VTX:COPN) Weak Earnings May Only Reveal A Part Of The Whole Picture

Consensus revenue estimates increase by 45%

Broker Revenue Forecasts For Cosmo Pharmaceuticals N.V. (VTX:COPN) Are Surging Higher

New minor risk - Earnings quality

Cosmo Pharmaceuticals N.V. to Report Fiscal Year 2023 Final Results on Apr 30, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Cosmo Pharmaceuticals N.V. to Report First Half, 2024 Results on Jul 25, 2024

Investor sentiment improves as stock rises 16%

Cosmo Pharmaceuticals N.V., Annual General Meeting, May 24, 2024

Cosmo Pharmaceuticals N.V.'s (VTX:COPN) Popularity With Investors Is Clear

Consensus EPS estimates fall by 10%

Earnings Beat: Cosmo Pharmaceuticals N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

First half 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus EPS estimates increase by 10%

Upcoming dividend of €1.05 per share at 2.0% yield

Consensus EPS estimates increase by 12%

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 11%

Cosmo Pharmaceuticals N.V., Annual General Meeting, May 26, 2023

We Think Cosmo Pharmaceuticals (VTX:COPN) Can Stay On Top Of Its Debt

No independent directors

Consensus forecasts updated

Consensus EPS estimates increase by 17%

First half 2022 earnings released

Cosmo Pharmaceuticals N.V. Announces Acceptance of NDA Submission of Cortiment® Mmx® in Japan

No independent directors

Cosmo Pharmaceuticals' (VTX:COPN) Solid Profits Have Weak Fundamentals

Cosmo Pharmaceuticals N.V. Proposes Cash Dividend

Forecast breakeven date pushed back to 2022

Non-Executive Director Eimear Cowhey has left the company

Non-Executive Director Eimear Cowhey has left the company

Non-Executive Director Eimear Cowhey has left the company

Non-Executive Director Eimear Cowhey has left the company

Non-Executive Director Eimear Cowhey has left the company

Non-Executive Director Eimear Cowhey has left the company

Non-Executive Director Eimear Cowhey has left the company

Non-Executive Director Eimear Cowhey has left the company

Non-Executive Director Eimear Cowhey has left the company

Non-Executive Director Eimear Cowhey has left the company

Non-Executive Director Eimear Cowhey has left the company

Non-Executive Director Eimear Cowhey has left the company

Non-Executive Director Eimear Cowhey has left the company

Non-Executive Director Eimear Cowhey has left the company

Non-Executive Director Eimear Cowhey has left the company

Non-Executive Director Eimear Cowhey has left the company

Non-Executive Director Eimear Cowhey has left the company

Non-Executive Director Eimear Cowhey has left the company

Non-Executive Director Eimear Cowhey has left the company

Non-Executive Director Eimear Cowhey has left the company